Opportunities to Optimize Cancer Policies Panel Discussion

First International Summit on Interventional Pharmacoeconomics

David A. Hyman, MD, JD, on Inclusive Shared Savings

Amit Sanyal, MD: A Clinician’s Perspective

Cody Peer, PhD, on Simulating Alternative Schedules for Checkpoint Inhibitors

Issues in Oncology

The ASCO Post Staff

Leonard B. Saltz, MD, on Interventional Pharmacoeconomics: A Pathway to Better Cancer Care

Leonard B. Saltz, MD, of Memorial Sloan Kettering Cancer Center, discusses interventional pharmacoeconomics as an important tool that can offer patients with cancer more efficacious and cost-effective care. Pharmacoeconomics may help reduce the high costs of cancer therapy, with evidence-based reductions in doses that maintain effective treatment.

Focus on Optimized Dosing of Ibrutinib Panel Discussion

Jan

Today In Oncology

Opportunities to Optimize Cancer Policies Panel Discussion

Related Videos

David A. Hyman, MD, JD, on Inclusive Shared Savings

Amit Sanyal, MD: A Clinician’s Perspective

Cody Peer, PhD, on Simulating Alternative Schedules for Checkpoint Inhibitors

Leonard B. Saltz, MD, on Interventional Pharmacoeconomics: A Pathway to Better Cancer Care

Focus on Optimized Dosing of Ibrutinib Panel Discussion

Can Color Vision Deficiency Impact Survival in Bladder or Colorectal Cancer

Comprehensive Multiomic Resource for HPV-Negative Head and Neck Cancers

Emergency Department Use and Unplanned Hospitalization Among Patients With Head and Neck Cancer

Reduced-Dose Intensity-Modulated Radiation Therapy for HPV-Associated Oropharyngeal Carcinoma

Endoscopic Nasopharyngectomy vs IMRT for Previously Treated, Resectable, Locally Recurrent Nasopharyngeal Carcinoma